These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24170263)

  • 21. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate.
    Smith P; Bullock JM; Booker BM; Haas CE; Berenson CS; Jusko WJ
    Pharmacotherapy; 2004 Nov; 24(11):1508-14. PubMed ID: 15537555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics interaction between imatinib and genistein in rats.
    Wang Z; Wang L; Xia MM; Sun W; Huang CK; Cui X; Hu GX; Lian QQ; Wang ZS
    Biomed Res Int; 2015; 2015():368976. PubMed ID: 25629045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs.
    Ishizuka M; Nagai S; Sakamoto KQ; Fujita S
    Xenobiotica; 2007 May; 37(5):503-13. PubMed ID: 17523053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats.
    Liu XY; Xu T; Li WS; Luo J; Geng PW; Wang L; Xia MM; Chen MC; Yu L; Hu GX
    Biomed Res Int; 2013; 2013():789184. PubMed ID: 24369535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates.
    Neville K; Parise RA; Thompson P; Aleksic A; Egorin MJ; Balis FM; McGuffey L; McCully C; Berg SL; Blaney SM
    Clin Cancer Res; 2004 Apr; 10(7):2525-9. PubMed ID: 15073132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
    Hernández-Boluda JC; Cervantes F
    Drugs Today (Barc); 2002 Sep; 38(9):601-13. PubMed ID: 12582448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors.
    De Giorgi U
    Future Oncol; 2013 Nov; 9(11):1675-7. PubMed ID: 23862700
    [No Abstract]   [Full Text] [Related]  

  • 28. Imatinib mesylate.
    Al-Hadiya BM; Bakheit AH; Abd-Elgalil AA
    Profiles Drug Subst Excip Relat Methodol; 2014; 39():265-97. PubMed ID: 24794909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory effect of silybin on pharmacokinetics of imatinib in vivo and in vitro.
    Wang L; Wang Z; Xia MM; Wang YY; Wang HY; Hu GX
    Can J Physiol Pharmacol; 2014 Nov; 92(11):961-4. PubMed ID: 25365188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588.
    Manley PW; Blasco F; Mestan J; Aichholz R
    Bioorg Med Chem; 2013 Jun; 21(11):3231-9. PubMed ID: 23611771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.
    Yoo C; Ryu MH; Ryoo BY; Beck MY; Kang YK
    Invest New Drugs; 2013 Oct; 31(5):1367-74. PubMed ID: 23591629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
    Gibbons J; Egorin MJ; Ramanathan RK; Fu P; Mulkerin DL; Shibata S; Takimoto CH; Mani S; LoRusso PA; Grem JL; Pavlick A; Lenz HJ; Flick SM; Reynolds S; Lagattuta TF; Parise RA; Wang Y; Murgo AJ; Ivy SP; Remick SC;
    J Clin Oncol; 2008 Feb; 26(4):570-6. PubMed ID: 18235116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec).
    Kil KE; Ding YS; Lin KS; Alexoff D; Kim SW; Shea C; Xu Y; Muench L; Fowler JS
    Nucl Med Biol; 2007 Feb; 34(2):153-63. PubMed ID: 17307123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
    Gambacorti-Passerini C; Zucchetti M; Russo D; Frapolli R; Verga M; Bungaro S; Tornaghi L; Rossi F; Pioltelli P; Pogliani E; Alberti D; Corneo G; D'Incalci M
    Clin Cancer Res; 2003 Feb; 9(2):625-32. PubMed ID: 12576428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
    Filppula AM; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2013 Jan; 41(1):50-9. PubMed ID: 23028140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules.
    Nikolova Z; Peng B; Hubert M; Sieberling M; Keller U; Ho YY; Schran H; Capdeville R
    Cancer Chemother Pharmacol; 2004 May; 53(5):433-8. PubMed ID: 15132131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
    Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
    Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors].
    García-González J; Sánchez Salmón A; Areses Manrique C; León Mateos L; Barandela Salgado J; López López R
    Rev Esp Med Nucl; 2007; 26(2):100-2. PubMed ID: 17386236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
    Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.